Researchers at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center have shown why a protein known as cyclin D1 may be the Achilles heel for breast tumors that are estrogen receptor positive (ER+) − which is the most common type of breast cancer.
In the December 10th online edition of the journal Oncogene, investigators say the findings support testing an experimental class of drugs that aim to inhibit the cyclin D1 protein in women with ER+ breast cancers. These agents are currently being tested in this disease as well as in many other types of cancer, the researchers say, and the study provides additional molecular support for their use in breast cancer.
“Everyone knows that cyclin D1 is a huge player in breast cancer, but no one has shown what happens when cyclin D1 is absent at the same time that the estrogen receptor is being over-expressed on tumors. Now we know the answers, and we hope these insights help further our understanding and treatment of breast cancer,” said the study’s lead author, Maria Silvina Frech, Ph.D., who is currently a postdoctoral researcher at the National Cancer Institute but who worked on the study at Georgetown.
“These findings give insight into how drugs that indirectly inhibit cyclin D1 function, either those in testing or ones to be developed, might help a significant number of women with breast cancer,” said Priscilla Furth, M.D., a professor at the Lombardi Comprehensive Cancer Center who is the study’s senior investigator.
Cyclin D1 belongs to a family of cyclin genes whose proteins regulate cyclin-dependent kinases (CDKs), which in turn control cell division. CDKs are the main facilitators of cell proliferation cycle. Over-production of the Cyclin D1 protein or amplification (extra copies) of the gene have been observed in a number of cancers, and this study continued a body of research in Furth’s lab that has examined the relationship between ER+ breast cancer and cyclin D1.
In 2005 Furth and Frech published a study that demonstrated that over expression of ERá (the main estrogen receptor subtype that mediates cell growth and is the major player in ER+ breast cancer) in mice resulted in the development of the earliest form of breast cancer, ductal carcinoma in situ (DCIS). They then found that cyclin D1 was over expressed in these lesions but not in the surrounding normal tissue. “Once the cancer process begins, cyclin D1 starts being over-expressed,” Frech said. “This was an exciting finding, but it was not clear what the precise role cyclin D1 plays in ER+ cancer.”
To find out what the protein was doing in these breast tumors, Frech, Furth, Kathleen Torre, B.S., from Georgetown and Gertraud W Robinson, Ph.D. from NIDDK, NIH, decided to take a genetics approach to the problem. They created an animal model that both over-expressed ERá and lacked cyclin D1.
They thought they would see a decreased incidence in DCIS in the animals, but what they actually found was that they completely lacked the mammary gland tissue that normally encases breast milk ducts. “This was very surprising. Most of the cells that usually make up the gland were absent, replaced by other structural tissue that shouldn’t be there,” she said.
t was also puzzling, Frech said, because puberty-induced mammary gland development in female mice that simply lack cyclin D1 is essentially normal. It made no sense to researchers that coupling over expression of ERá with the absence of cyclin D1 would have a complete lack of mammary glands. “This was striking, very unusual,” she said.
The solution was also very challenging, said Frech, whose three years of work on the project earned her a Ph.D. They eventually found that when cyclin D1 is deleted, levels of another major cyclin family member − cyclin E − are increased. And over-production of cyclin E, in the developing gland of these ERá over expressing mice led to DNA damage and cell death. The question that remains unanswered is whether this situation would hold true in advanced cancers treated with agents that inhibit cyclin D1 function, she said.
They also discovered that while cyclin D1 was not necessary for maintenance of normal breast cells, it was essential for the proliferation of abnormal mammary gland cells − and this differential use of cyclin D1 seems to be unique to early breast cancer. “That supports the idea that reducing cyclin D1 in breast cancer cells would not harm normal cells,” she said. There are experimental agents now being tested in clinical trials that shut down cyclin D1 function by targeting CDKs, Frech said. For example, flavopiridol is a potent CDK inhibitor currently undergoing clinical trials for a variety of tumors including breast cancer. Clinical activity is encouraging when used in combination with other molecular targeted agents, she said.
The study was supported by grants from the Department of Defense and the National Institutes of Health.About Lombardi Comprehensive Cancer Center
Becky Wexler | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences